

TWO DECADES OF TRANSFORMATION UNDER MILES WHITE

1999	<ul style="list-style-type: none"> Miles D. White takes over as Abbott chairman and CEO. The company serves customers in 130 countries, has approximately 57,000 employees, sales of \$12.5 billion with more than 60% in the U.S., and a market capitalization of \$75 billion. Acquires Perclose, providing the foundation for building the company's leading cardiovascular business.
2000	<ul style="list-style-type: none"> Begins unique public-private partnership in Tanzania to strengthen the country's healthcare system, investing more than \$130 million during the next two decades. The partnership strengthens treatment and care, including a modern ER that decreased hospital mortality rates by 40 percent.
2001	<ul style="list-style-type: none"> Acquires Knoll Pharmaceuticals, jump-starting the company's portfolio and pipeline. Abbott developed and launched Humira[®], which would become the world's leading drug.
2003	<ul style="list-style-type: none"> Establishes Point-of-Care business, enabling rapid, near-patient testing, with the acquisition of i-STAT.
2004	<ul style="list-style-type: none"> Spins off the hospital products business as Hospira, an independent, publicly traded company. Pfizer later buys Hospira for \$17 billion in 2015. Acquires TheraSense, a leading blood-glucose monitoring business, setting the stage for what is now a market-leading diabetes care business.
2005	<ul style="list-style-type: none"> Earns place on the Dow Jones Sustainability Index, one of the most prestigious benchmarks for sustainable, responsible business practices; company has remained on list for 15 years, leading the healthcare industry for the past seven years.
2006	<ul style="list-style-type: none"> Acquires Guidant's vascular business, further expanding the company's growing medical device and heart care businesses through leading products like the XIENCE drug-eluting stent. Creates fully-integrated global nutrition business. Sales of its international division have nearly tripled to \$4.2 billion since its formation.
2010	<ul style="list-style-type: none"> Acquires Solvay's pharmaceutical business, providing a diverse branded generics portfolio and significant presence in key emerging markets. Forms a stand-alone Established Pharmaceuticals business, a unique model in the industry focused solely on providing branded generic medicines in emerging markets. Acquires Piramal's Healthcare Solutions business in India, bolstering Abbott's branded generics business by making it a leader in the large Indian pharmaceutical market.
2013	<ul style="list-style-type: none"> Separates its research-based pharmaceutical business into a new public company called AbbVie. Today, the combined market capitalization of the companies has risen 167% to \$277 billion.
2014	<ul style="list-style-type: none"> FreeStyle Libre[®], the world's first continuous glucose-monitoring system (CGM) to eliminate fingersticks, is approved in Europe. It was later approved for use in the U.S. and is the No. 1 CGM in the world. Expands Established Pharma business with the acquisitions of CFR Pharmaceuticals in Latin America and Veropharm in Russia, further enhancing its presence in fast-growing markets.
2016	<ul style="list-style-type: none"> Launches Alinity[™], a family of six diagnostics systems, across all of Abbott's laboratory testing segments, marking an unprecedented reimagination of the testing platforms for the company and the industry.
2017	<ul style="list-style-type: none"> Acquires St. Jude Medical, creating a medical device leader with top positions in high-growth cardiovascular markets and a leader in neuromodulation to treat chronic pain and movement disorders. Creates the world's leading point-of-care diagnostics business through the acquisition of Alere.
2019	<ul style="list-style-type: none"> Ranks No. 1 in its industry among Fortune's Most Admired companies for the sixth straight year. Abbott is one of 52 from the original Fortune 500 and just 59 from the initial S&P 500 to remain on those lists. Abbott's stock reaches all-time high. Mr. White has created \$220 billion in shareholder value and a total return of 575%,² well ahead of the Dow Jones Industrial Average (393%) and S&P 500 (274%) over the same timeframe. Abbott's sales have grown to \$30.6 billion today with 65% in international markets and a market cap of \$149 billion (excluding AbbVie and Hospira). The company now has 103,000 employees serving people in more than 160 countries.

1 Humira[®] is a registered trademark of AbbVie, Inc.

2 Includes the combined market capitalization of Abbott, AbbVie and Hospira (\$294 billion)